Aurinia Pharmaceuticals's (AUPH) Outperform Rating Reiterated at FBR Following AURA-LV Phase IIb Data
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/19/2024
- Nasdaq, S&P stumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Wall St indexes split, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Aurinia Pharmaceuticals' (AUPH) Price Target Raised to $10 at H.C. Wainwright
August 17, 2016 9:00 AM EDTH.C. Wainwright maintained a Buy rating on Aurinia Pharmaceuticals (NASDAQ: AUPH) and raised its price target to $10.00 (from $7.00). Comments follow the release of AURA-LV trial earlier this week.
Analyst Ed Arce said investors focused only on the number of deaths, and appeared to attribute them largely to voclosporin, in spite of the natural history of the... More
Leerink Partners Reiterates 'Outperform' on Aurinia Pharmaceuticals (AUPH) Following Phase 2b AURA-LV Results
August 15, 2016 9:46 AM EDTLeerink Partners reiterated an Outperform rating on Aurinia Pharmaceuticals (NASDAQ: AUPH) following the release of top-line results from the Phase 2b AURA-LV (AURA) clinical study in patients with active lupus nephritis (LN). Analyst Joseph P. Schwartz noted that the study hit on efficacy.
In the analyst's view, the stock is down significantly as a result of an excess number of deaths for patients receiving the drug. However, he thinks it is important to be mindful that these lupus nephritis patients were extremely sick and treated at many sites. The company noted that... More
Aurinia Pharmaceuticals (AUPH) Announces Significant Data from Phase 2b AURA-LV in LN
August 15, 2016 6:08 AM EDTAurinia Pharmaceuticals (NASDAQ: AUPH) announced positive top-line results from the Phase 2b AURA-LV (AURA) clinical study in patients with active lupus nephritis (LN). The trial achieved its primary endpoint, demonstrating statistically significantly greater complete remission (CR) (as defined by confirmed urinary protein/creatinine ratio of 0.5 mg/mg at 24 weeks and confirmed at 26 weeks) in patients treated with 23.7 mg of voclosporin twice daily (p=0.045). Both treatment arms, 23.7 mg and 35.9 mg twice daily also showed a statistically significant improvement in the rate of achieving partial remission (PR) at 24 weeks (p=0.007; p=0.024). Each arm of the study... More
Aurinia Pharmaceuticals' (AUPH) Voclosporin Phase 2b AURA-LV Study Meets Primary Endpoint in Lupus Nephritis
August 15, 2016 6:08 AM EDTAurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced positive top-line results from the Phase 2b AURA-LV (AURA) clinical study in patients with active lupus nephritis (LN). The trial achieved its primary endpoint, demonstrating statistically significantly greater complete remission (CR) (as defined by confirmed urinary protein/creatinine ratio of 0.5 mg/mg at 24 weeks and confirmed at 26 weeks) in patients treated with 23.7 mg of voclosporin twice daily (p=0.045). Both treatment arms, 23.7 mg and 35.9 mg twice daily also showed a statistically significant improvement in the rate of achieving partial remission (PR) at 24 weeks (p=0.007; p=0.024). Each arm of... More
